Renaissance Capital logo

Semnur Pharmaceuticals (Denali Capital Acquisition) Priced, Nasdaq: SMNR

Fourth blank check company formed by the CEO of US Tiger Securities (completed 9/22/2025).

Industry: SPAC

First Day Return: +0.2%

Industry: SPAC

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target, and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. We are focused on identifying unique business concepts with high-performing organizations that have both aspirations to accelerate growth and create enduring value within the technology, hospitality, or consumer services sectors.
more less
IPO Data
IPO File Date 03/01/2022
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 7.5
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/06/2022
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $75
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New York, NY, United States
Founded 2022
Employees at IPO 1

Semnur Pharmaceuticals (Denali Capital Acquisition) (SMNR) Performance